Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Lillys blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity
Payers will take notice of this in addition to the timing aspect with respect to when the benefits accrue, the non-generalizability of the data, the high price of Wegovy per patient and the potentially substantial financial exposure they incur if they cover the drug
The result matters, but the flag alone is not the diagnosis
When you're eating less food overall, every bite matters more
US$ 21.24
US$ 26.40
US$ 26.48
US$ 28.89
US$ 27.36
US$ 25.69
US$ 29.06
US$ 28.90
US$ 27.65
